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Central venous catheter-associated venous thromboembolism in patients with cancer. 
Central venous catheters (CVC) are increasingly used in medical practice world-wide and, regardless the 
differences among the various CVC,1 these devices cause an increased risk of venous thromboembolism 
(VTE).2 The magnitude of the problem is highly dependent on whether we consider symptomatic (0.3-
28.3%) or asymptomatic VTE (27-66%),2 and the diagnostic imaging technique used, being venography the 
most sensitive one.2 At any rate, CVC-associated VTE represents a major clinical problem in terms of 
venous access loss, pulmonary embolism and additional costs.3 
This issue may be of even greater relevance in cancer patients who combine the need of CVC insertion with 
an intrinsic increased risk of VTE related to the tumor itself. Therefore, the question on how to reduce the 
risk of VTE in cancer patients harboring CVC is not trivial. Of course, the expected benefit of any 
prophylactic treatment is highly dependent on the absolute VTE risk that vary according to the different 
tumor histotypes and clinical presentations (e.g., pancreatic cancer or mediastinal syndrome).2 Several 
authors explored whether or not anticoagulant therapies (AT) (low-molecular weight heparin or vitamin K 
antagonists) can prevent CVC-associated VTE.1 In general, published data did not support systematic use of 
AT,1,3,4 but there are some conflicting data.5 This relative uncertainty prompted us to review the literature 
searching for randomized studies on the role of AT in the prevention of VTE in cancer patients harboring 
CVC.  
On this specific issue we could identify 12 papers (most included in a recent Cochrane meta-analysis) 
suitable to evaluate the benefit of AT in cancer patients to prevent CVC-associated VTE.4,5 Our analysis was 
focused on symptomatic VTE only, because previous analyses did not demonstrate a statistically significant 
increase in bleeding risk,2,3,4,5 and we did not consider the prevention of asymptomatic VTE as a convincing 
endpoint.  
In detail, data from 3018 patients enrolled in 12 randomized trials were included in this meta-analysis. 
Summary of Mantel-Haenszel risk ratios was calculated using a random-effects model. Our meta-analysis 
(Figure 1) suggests that AT compared to no active treatment significantly reduces the risk of symptomatic 
VTE (risk ratio = 0.61; 95% CI: 0.42-0.88). The absolute incidence of VTE was reduced from 6.8% to 3.7% 
(p=0.0001) with 32 patients (95% CI: 21-65) needed to be treated to prevent one event. Although our 
findings argue in favor of AT for the prevention of CVC-associated VTE in cancer patients, only a large 
prospective randomized trial will definitely answer this question. 
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Legend:  Figure 1. Meta-analysis of randomized trials comparing anticoagulation therapies (either 
heparin or vitamin K antagonists) vs. untreated controls for symptomatic venous thromboembolism 
(VTE) in cancer patients harboring a central venous catheter. 
* The trial by Couban and Colleagues was excluded from previous Cochrane Review4 because of differential 
follow-up relative to randomization between the two arms (63 days for the warfarin group and 84 days for 
the placebo group). 
** Regarding the trial of Ruud and Colleagues, we considered VTE as symptomatic in the presence of all the 
following three criteria: non compressibility of vein, absence of flow and presence of completely occluding 
thrombus. 
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